PetVivo Holdings, Inc.
PETVAbout the company
PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals in the United States. The company's lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses.
Investment snapshot
Positive
2
BUY / PASS
Neutral / negative
1 / 13
NEUTRAL / FAIL
Median fair value
—
No comparable estimates
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 13 investors flag at least one valuation criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | FAIL · Rank #2954 (Top 95.4%) | PASS | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | PASS | FAIL | FAIL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025 Latest source filing: 2026-08-14 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 Latest source filing: 2026-08-14 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-06-30 · TTM ended 2026-06-30 vs 2025-06-30 · TTM ended 2026-06-30 Latest source filing: 2026-08-14 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-06-29 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-06-29 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01 Latest source filing: 2026-08-14 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-14 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-06-29 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-06-30 Latest source filing: 2026-08-14 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 · Qualitative assessment Latest source filing: 2026-08-14 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01 Latest source filing: 2026-08-14 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-14 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-06-29 Score computed: 2026-11-14 | TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-08-14 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-06-29 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-14 Score computed: 2026-11-14 | TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-08-14 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Valuation0% pass✓ 1✗ 27▾
No clean pass — all 13 investors flag at least one valuation criterion
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio8.4x✗Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-46.1%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-46.1%, ROC=-1240.3%✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xPrice / Book Value per Share8.4x✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Valuation ReasonablenessOE Yield=-54.0%✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=-31.3%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/B=8.4x✗MarksP/E < 15 or P/B < 2.0Discount to Intrinsic Value✗Marks>= 20% below intrinsic valuePrice / FCF per ShareN/A (negative FCF)✗Ackman<= 25Price vs. Trailing Low100% of trailing low ($0.51)✓Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-50.02%; #5050/6340 (top 79.7%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+0.0694; #4902/6449 (top 76.0%)✗AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per Share8.47x✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+0.0605; #4520/5247 (top 86.1%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-31.29%; #3669/4519 (top 81.2%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date-32.15%; #4504/6202 (top 72.6%)✗OshaughnessyTop 10% of eligible cross-section - Cash Flow0% pass✓ 1✗ 11▾
No clean pass — all 10 investors flag at least one cash flow criterion
Free Cash Flow Proxy$-10.0M✗BuffettPositive and growingFCF Positive and Growing$-6.1M✗LynchPositive and growingOperating Cash Flow$-6.1M✗PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=-170.75%, ROA=-292.83%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xP/E or FCF YieldFCF Yield=-31.3%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive0/10 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-33.1%✗Ackman>= 4%Price / FCF per ShareN/A (negative FCF)✗Ackman<= 25Positive Operating Cash Flow frequency0/14 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-6.1M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-31.29%; #3669/4519 (top 81.2%)✗OshaughnessyTop 10% of eligible cross-section - Profitability6% pass✓ 4✗ 31▾
15 of 16 flag PETV's profitability — Graham, Buffett, Lynch +12 more
Positive EPS (10 years)0/17 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthNet Income Positive (10+ years)0/17 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-711.7%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-793.9% (latest)✓BuffettStable or rising over 10 yearsFree Cash Flow Proxy$-10.0M✗BuffettPositive and growingEarnings Variance (10-yr CoV)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE-720.9%✗Lynch> 15%EBIT / Enterprise Value-46.1%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-46.1%, ROC=-1240.3%✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-292.83%✗PiotroskiROA > 0ROA Change YoY-89.93% -> -292.83% (delta: -202.89%)✗PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=-170.75%, ROA=-292.83%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY87.8% -> 66.1%✗PiotroskiImproved YoYPre-Tax Income / Revenue-827.3%✗Dreman>= 8%Net Income / Shareholders' Equity-720.9%✗Dreman> 12%Margin of SafetyP/B=8.4x✗PabraiP/B < 1.5 or P/E < 15Return on Equity-757.5% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic Value✗Marks>= 20% below intrinsic valuePositive Net Income Frequency0/16 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue-747.0%✗Ackman>= 15%Net Income / Shareholders Equity-720.9%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-1096.4% (2023) -> -793.9% (2025)✓TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 89.5% -> 66.1%, operating margin -1096.4% -> -793.9%✓SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-50.02%; #5050/6340 (top 79.7%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+29.64%; #1456/3702 (top 39.3%)✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity-720.89%; #5122/5226 (top 98.0%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-1.2727; #5342/5884 (top 90.8%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years0/9 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Growth13% pass✓ 4✗ 9▾
7 of 8 flag PETV's growth — Graham, Lynch, Dreman +4 more
EPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthInv: -14.7% vs Rev: -9.5%✓LynchInventory growth < Revenue growthEPS Growth Direction✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency0/16 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth5.6%✓Ackman>= 5%Positive EPS Growth Frequency✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 89.5% -> 66.1%, operating margin -1096.4% -> -793.9%✓SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR146.4%✓SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Efficiency13% pass✓ 2✗ 9▾
7 of 8 flag PETV's efficiency — Graham, Buffett, Greenblatt +4 more
Current Ratio0.72✗Graham>= 2.0ROIC (3-5 yr avg)-14790.9%✗Buffett> 10%ROIC - WACC-14800.9%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)-1240.3%✗Greenblatt> 25%Current Ratio Change YoY1.30 -> 1.35✓PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.12x -> 0.32x✓PiotroskiImproved YoYCurrent Assets / Current Liabilities0.72✗Dreman> 1.5Return on Invested Capital-380.5%✗Munger> 15%ROIC (high and growing)FY2023: ROIC=-1187.7%; FY2024: ROIC=-140.3%; FY2025: ROIC=-284.0%✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROICN/A (non-positive net income)✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)0/5 years above 12% (latest -284.0%)✗SleepROIC > 12% in a majority of years - Verdicts13% pass✓ 2✗ 14▾
Split decision: 13 FAIL · 2 PASS · 1 NEUTRAL
Overall verdict✗GrahamFAIL (0/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)✗GreenblattRank #2954✓PiotroskiPASS (F-Score 4)✗DremanFAIL (1/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✗AckmanFAIL (3/9)✓TempletonPASS (4/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #2328/2370 (Top 98.2%))✗NeffFAIL (1/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked) - Debt & Leverage33% pass✓ 6✗ 9▾
8 of 12 flag PETV's debt & leverage — Graham, Buffett, Lynch +5 more
Debt Levels0.35✓MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3LT Debt vs Net Current Assets✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: 0.35, IC: -9.3x✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity0.35✗Lynch< 0.33Cash - Long-term Debt✗LynchPositive preferredLT Debt / Total Assets Change0.00% -> 0.00%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities0.72✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity0.35✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00xInterest Coverage & Debt/EBITDAIC=-9.3x, D/EBITDA=N/A✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity0.35✓Ackman<= 1.0Negative debt-to-equity (higher means less debt)-0.3513; #2134/4210 (top 50.7%)✗AsnessTop 30% of eligible cross-section
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 47.0% of shares last year, 110.2% issued over two.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-06-30 2025-07-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense, capex. | Q1 FY 2027 2026-04-01 – 2026-06-30 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|
| Market Cap | $19.5Mcurrent | -- | $35.1Mest. | $19.5Mest. | $21.1Mest. | $29.0Mest. | $12.8Mest. |
| Revenue | $1.2M↓10% | $337.6K↑13% | $1.1M↑1% | $1.1M↑17% | $968.7K↑6% | $917.2K↑693% | $115.6K |
| Operating Income | -$8.8M↓12% | -$1.6M↑13% | -$9.1M↓13% | -$8.1M↑24% | -$10.6M↓22% | -$8.7M↓73% | -$5.1M |
| Net Income | -$9.8M↓13% | -$1.6M↑30% | -$10.5M↓25% | -$8.4M↑23% | -$11.0M↓26% | -$8.7M↓74% | -$5.0M |
| EPS (Diluted) | -- | $-0.05↑44% | $-0.38↑7% | $-0.41↑47% | $-0.78↑8% | $-0.85 | -- |
| Gross Margin | 67.0%↓18% | 66.2%↑5% | 66.1%↓25% | 87.8%↓2% | 89.5%↑18% | 75.9%↑203% | -74.0% |
| Operating Margin | -747.0%↓24% | -476.6%↑23% | -793.9%↓12% | -711.3%↑35% | -1096.4%↓15% | -952.2%↑78% | -4374.7% |
| ROE | -720.9%↓210% | — | -476.2%↓139% | -199.1%↑88% | -1597.1%↓33% | -1202.4%↓1335% | -83.8% |
| Total Debt | $476.5K↑5965% | $476.5K↑5965% | $321.4K↑1% | $318.3K↑1451% | $20.5K↓25% | $27.4K↓19% | $33.8K |
| Shareholders' Equity | $1.4M↓64% | $1.4M↓64% | $2.2M↓48% | $4.2M↑515% | $686.0K↓5% | $725.0K↓88% | $6.0M |
| Current Ratio | 0.72↓49% | 0.72↓49% | 1.35↑4% | 1.30↑76% | 0.74↓25% | 0.98↓83% | 5.76 |
| Debt / Equity | 0.35↑16585% | 0.35↑16585% | 0.15↑94% | 0.08↑152% | 0.03↓21% | 0.04↑569% | 0.01 |
| Operating Cash Flow | -$5.4M | -$965.8K↑41% | -$6.1M↓15% | -$5.3M↑28% | -$7.4M↓9% | -$6.8M↓63% | -$4.2M |
| Free Cash Flow | -- | -$978.1K | -$6.1M↓14% | -$5.4M↑30% | -$7.7M↓7% | -$7.2M↓67% | -$4.3M |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Medical Equipment
PETV vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALCON INCALC | $35.6B | $74.12 | $10.4B | $980.0M | 4.4% | 0.21 | 13.1% | 2.12 | 2/9 | 1/9 | 3/7 | 0/3 | F-Score 6 | 4/11 |
| KONINKLIJKE PHILIPS NVPHG | $29.7B | $30.34 | $21.0B | $1.1B | 8.2% | 0.64 | 8.0% | 1.32 | 1/9 | 1/9 | 1/7 | 0/3 | F-Score 5 | 3/11 |
| WEST PHARMACEUTICAL SERVICES INCWST | $29.0B | $416.42 | $3.1B | $493.7M | 15.5% | 0.06 | 19.0% | 3.02 | 4/9 | 6/9 | 6/7 | 1/3 | F-Score 7 | 5/11 |
| SMITH & NEPHEW PLCSNN | $13.1B | $31.28 | $6.2B | $625.0M | 11.8% | 0.59 | 12.9% | 2.57 | 2/9 | 0/9 | 1/7 | 0/3 | F-Score 6 | 4/11 |
| MSA Safety IncMSA | $6.7B | $174.17 | $1.9B | $278.9M | 20.4% | 0.42 | 19.8% | 3.01 | 5/9 | 5/9 | 4/7 | 1/3 | F-Score 5 | 7/11 |
| STAAR SURGICAL COSTAA | $1.3B | $26.39 | $239.4M | $80.4M | -23.4% | — | -38.3% | 4.55 | 2/9 | 2/9 | 2/7 | 0/3 | F-Score 3 | 3/11 |
| ARTIVION, INC.AORT | $931.9M | $19.10 | $441.3M | $9.8M | 2.2% | 0.48 | 7.6% | 3.53 | 2/9 | 0/9 | 0/7 | 0/3 | F-Score 7 | 1/11 |
| InMode Ltd.INMD | $763.6M | $13.27 | $370.5M | $93.8M | 13.7% | — | 23.0% | 9.88 | 5/9 | 3/9 | 0/7 | 3/3 | F-Score 4 | 4/11 |